LumiraDX And BIVDA Speak On Challenges Of Driving Adoption Of Valuable Diagnostics
Diagnostics such as c-reactive protein tests are more sensitive than ever before, but manufacturers are still struggling to place them in primary care and community settings where they can make huge differences.
You may also be interested in...
Founded with a vision to change point-of-care diagnostics, Osler Diagnostics has raised nearly $200m to develop and commercialize a platform that promises to revolutionize diagnostics with just a drop of a patients’ blood.
In a discussion with Medtech Insight, analysts at Ladenburg Thalmann argued the case for their LumiraDX $14.75 price target.
The diagnostic company has secured more government funding for DeepView, a product it has developed to assess the healing of certain types of wound. In total, BARDA has supported SpectralMD with almost a quarter of a billion dollars.